Nutralliance signed an exclusive sales and distribution agreement with KÄÄPÄ Biotech Ltd. for its Nordic Mushrooms wholesale mushroom extract product line.
Ultrasonic Assisted Extraction technology in KÄÄPÄ Biotech’s headquarters
Nutralliance (Yorba Linda, CA) signed an exclusive sales and distribution agreement with Finland-based KÄÄPÄ Biotech Ltd. for its Nordic Mushrooms wholesale mushroom extract product line, which includes Finnish-grown, organic mushrooms: chaga (Inonotus obliquus), reishi (Ganoderma lucidum), lion’s mane (Hericum erinaceus), shiitake (Lentinula edodes) and cordyceps (Cordyceps militaris).
“There is an increased demand for high-quality medicinal mushroom products in the North American market area,” said Eric Puro, CEO of KÄÄPÄ Biotech, in a press release. “The origin of the ingredients used in the food supplement industry is getting more important all the time. Our products are 100% of Finnish origin, from the FSC-certified Finnish sawdust substrate, to growing of mushrooms as well as processing and manufacturing of the mushroom extracts. We have full traceability and transparency in our process from spore to shipment. Therefore, we can guarantee premium quality mushroom extracts to the market.”
KÄÄPÄ Biotech invested in ultrasonic assisted extraction technology that utilizes a combination of hot water and alcohol extraction to ensure the extraction of the desired bioactive compounds in each mushroom. The Nordic Mushrooms product line includes mushroom extract powders and liquid extracts.
“The fungi kingdom and especially members of the Basidiomycota phylum (mushrooms) hold tremendous potential for natural, safe, and effective products that support a wide variety of health concerns as well as general well-being,” said Brian Salerno, CEO of Nutralliance. “To adequately fulfill modern North American consumers’ desires for superior quality in efficacy, safety, and traceability as well as sustainability, we wanted to ensure our mycological expert source was able to put checkmarks in all those columns. KÄÄPÄ Biotech is that resource.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”